Literature DB >> 27498187

Poly(phosphorhydrazone) dendrimers: yin and yang of monocyte activation for human NK cell amplification applied to immunotherapy against multiple myeloma.

Mary Poupot1, Cédric-Olivier Turrin2, Anne-Marie Caminade2, Jean-Jacques Fournié1, Michel Attal3, Rémy Poupot4, Séverine Fruchon5.   

Abstract

Human natural killer (NK) cells play a key role in anti-cancer and anti-viral immunity, but their selective amplification in vitro is extremely tedious to achieve and remains one of the most challenging problems to solve for efficient NK cell-based immuno-therapeutic treatments against malignant diseases. Here we report that, when added to ex vivo culture of peripheral blood mononuclear cells from healthy volunteers or from cancer patients with multiple myeloma, poly (phosphorhydrazone) dendrimers capped with amino-bis(methylene phosphonate) end groups enable the efficient proliferation of NK cells with anti-cancer cytotoxicity in vivo. We also show that the amplification of the NK population relies on the preliminary activation of monocytes in the framework of a multistep cross-talk between monocytes and NK cells before the proliferation thereof. Thus poly(phosphorhydrazone) dendrimers represent a novel class of extremely promising drugs to develop NK-cell based anti-cancer therapies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Dendrimers; Monocytes; Multiple myeloma; NK cells

Mesh:

Substances:

Year:  2016        PMID: 27498187     DOI: 10.1016/j.nano.2016.07.009

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  12 in total

1.  The Yin-Yang Dynamics in Cancer Pharmacogenomics and Personalized Medicine.

Authors:  Qing Yan
Journal:  Methods Mol Biol       Date:  2022

2.  An Anti-Inflammatory Poly(PhosphorHydrazone) Dendrimer Capped with AzaBisPhosphonate Groups to Treat Psoriasis.

Authors:  Ranime Jebbawi; Abdelouahd Oukhrib; Emily Clement; Muriel Blanzat; Cédric-Olivier Turrin; Anne-Marie Caminade; Eric Lacoste; Séverine Fruchon; Rémy Poupot
Journal:  Biomolecules       Date:  2020-06-23

Review 3.  The ABP Dendrimer, a Drug-Candidate against Inflammatory Diseases That Triggers the Activation of Interleukin-10 Producing Immune Cells.

Authors:  Séverine Fruchon; Rémy Poupot
Journal:  Molecules       Date:  2018-05-25       Impact factor: 4.411

Review 4.  Which Dendrimer to Attain the Desired Properties? Focus on Phosphorhydrazone Dendrimers.

Authors:  Anne-Marie Caminade; Jean-Pierre Majoral
Journal:  Molecules       Date:  2018-03-09       Impact factor: 4.411

5.  Biodistribution and Biosafety of a Poly(Phosphorhydrazone) Dendrimer, an Anti-Inflammatory Drug-Candidate.

Authors:  Séverine Fruchon; Elisabeth Bellard; Nicolas Beton; Cécile Goursat; Abdelouahd Oukhrib; Anne-Marie Caminade; Muriel Blanzat; Cédric-Olivier Turrin; Muriel Golzio; Rémy Poupot
Journal:  Biomolecules       Date:  2019-09-11

Review 6.  Main-Chain Phosphorus-Containing Polymers for Therapeutic Applications.

Authors:  Paul Strasser; Ian Teasdale
Journal:  Molecules       Date:  2020-04-08       Impact factor: 4.411

Review 7.  Phosphorus Dendrimers as Nanotools against Cancers.

Authors:  Anne-Marie Caminade
Journal:  Molecules       Date:  2020-07-22       Impact factor: 4.411

Review 8.  Targeted Delivery Methods for Anticancer Drugs.

Authors:  Valery V Veselov; Alexander E Nosyrev; László Jicsinszky; Renad N Alyautdin; Giancarlo Cravotto
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 9.  Repolarization of Unbalanced Macrophages: Unmet Medical Need in Chronic Inflammation and Cancer.

Authors:  Yannick Degboé; Rémy Poupot; Mary Poupot
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 10.  AB5 Derivatives of Cyclotriphosphazene for the Synthesis of Dendrons and Their Applications.

Authors:  Artem Zibarov; Abdelouahd Oukhrib; Julien Aujard Catot; Cédric-Olivier Turrin; Anne-Marie Caminade
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.